Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck’s Keytruda Missed Survival Goal in Phase III Study

By Ryan Bushey | July 25, 2017

A blockbuster cancer drug hit a road block on its path toward clinical development.

Merck reported pembrolizumab (Keytruda) did not meet the pre-specified primary endpoint of overall survival in a phase III study focusing on previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

“We are encouraged by the positive impact that KEYTRUDA has had on many cancer patients, including those with previously treated recurrent or metastatic head and neck cancer, and we remain confident that KEYTRUDA is an important therapy for this difficult-to-treat cancer,” said Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “We look forward to sharing the comprehensive data analysis from KEYNOTE-040 with the scientific community at an upcoming medical meeting.”

While the company didn’t release specific data, it noted the safety profile for the treatment was consistent with previous observations.

The U.S. Food and Drug Administration (FDA) gave Merck fast-track approval last August for Keytruda based on a subset of data that indicated the drug was shrinking tumors, reported Xconomy. The agency required positive results be presented in the future especially evidence of a survival benefit over standard chemotherapy.

However, Merck said in a statement that the current indication remains unchanged and clinical trials for the drug will continue.

The company’s clinical development program for this drug includes tests for over 30 tumor types in over 500 clinical trials. About 300 of these investigations are testing the drug’s efficacy in conjunction with other oncology treatments.

Ultimately, this news could alter the dynamic between Merck and Bristol-Myers Squibb (BMS) as they jockey for control over the immunotherapy space. BMS’s Opdivo received FDA approval in November 2016 for head and neck cancer based on overall survival data.


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50